Introduction {#s1}
============

Pain is a debilitating part of the experience of metastatic cancer. An automated system to categorize and track pain in electronic medical records could provide a powerful means to improve clinical care, and could allow novel 'high pain' or 'low pain' phenotypes to be defined and studied on a molecular basis. We tested the feasibility of using natural language processing (NLP) of text from clinical encounters to depict meaningfully the experience of pain in patients with metastatic prostate cancer over time.

Background {#s2}
==========

Worldwide, prostate cancer is the second most commonly diagnosed cancer and the sixth leading cause of cancer death in men.[@R1] In the past decade, significant effort has been made to better understand and reduce the burden of pain on the cancer patient,[@R2; @R3; @R4; @R5] the patient\'s family, caregivers, and society.[@R6] Pain status can predict survival in metastatic prostate cancer,[@R7] and changes in pain status have been examined as a surrogate marker of effectiveness of new therapies.[@R8] [@R9] Several validated pain survey tools have been proposed for routine clinical care.[@R10] [@R11]

NLP has been used to quantify associations between diseases, conditions, and symptoms,[@R12; @R13; @R14; @R15; @R16] for vocabulary discovery,[@R17] and for cohort construction.[@R18; @R19; @R20; @R21; @R22; @R23; @R24; @R25] NLP applications focusing on pain in clinical records have successfully detected the experience of pain in free text within an electronic medical record.[@R26; @R27; @R28] Some studies suggest that, in some scenarios, NLP of medical record text may perform better than patient-completed surveys in detection of clinically relevant pain.[@R26] [@R28]

Although pain has previously been normalized and classified *manually* for purposes of statistical correlations,[@R29] we used NLP to *automatically* characterize the experience of pain over thousands of records. To our knowledge, this is the first study to combine NLP, date resolution, and statistical analysis to create a longitudinal study of pain in the clinical record. Our system normalized each mention of pain in longitudinal clinical records by severity classification and number of days before death. We used regression modeling techniques to analyze both the newly structured data and the existing structured data to search for phenotypic correlations with pain in the context of metastatic prostate cancer.

Pain management is fundamental to effective clinical care, and significant pain is a consequence of the disordered biology of many cancers. This study tests the feasibility of automatically tracking patient pain over time using NLP of clinical record text. If NLP-based pain tracking is feasible, further study will be indicated to test the hypothesis that adoption of NLP-based pain tracking within electronic health record systems could provide significant added value in clinical care and in advancing research in disease phenotyping.

Methods {#s3}
=======

Patient cohort {#s3a}
--------------

Thirty-three men from the PELICAN (Project to ELIminate lethal CANcer) integrated clinical/molecular autopsy study of metastatic prostate cancer were the subjects of this study. Subjects joined the institutional review board-approved study between 1995 and 2005. The mean age of the study subjects at the time of diagnosis of prostate cancer was 62 years (range 42--75). The mean interval between diagnosis and death was 6.3 years (range 0.8--15.4). Of the 33 subjects in the study, 27 were Caucasian, five were African-American, and one was of Hispanic background. Six subjects were seen only in community hospital inpatient, clinic and private office settings; the remaining 27 subjects were followed in a combination of oncology center and community hospital clinic settings.

Clinical records obtained {#s3b}
-------------------------

The study obtained and analyzed all available paper, electronic, radiologic, radiation therapy, and pathology medical records for each subject. Subjects provided a list of institutions and physician offices where medical care was received, and copies of medical records from the various institutions and offices were obtained.

Creation of electronic records for each study subject {#s3c}
-----------------------------------------------------

A total of 23 887 pages of paper records were converted into electronic text using methods described in the online appendix. The electronic record included laboratory values, radiology reports, pathology reports, and records of inpatient and outpatient encounters with providers. The text recorded in 4409 inpatient and outpatient encounters is called the 'PELICAN corpus' and is the focus of this study.

Integrated Life Sciences Research (ILSR) database and removal of identifiers {#s3d}
----------------------------------------------------------------------------

The full curated electronic text of each paper record was placed in the ILSR database, a system created to support the PELICAN Study. The average number of inpatient or outpatient records per year between diagnosis and death was 32 (range 4--212). Subject date of birth, date of death, race/ethnicity, all available serum prostate-specific antigen (PSA) concentrations, body weight measurements, body height measurements, and radiation therapy records were separately tabulated in ILSR by project data curators.

Pain status categorization {#s3e}
--------------------------

A multidisciplinary team consisting of NLP software developers, medical subject matter experts (SMEs), and statisticians developed a pain categorization model based on a conservative four-tiered pain scale: no pain (category 0); some pain (category 1); controlled pain (category 2); severe pain (category 3).

Natural language processing {#s3f}
---------------------------

We used ClinREAD, a proprietary healthcare-domain-oriented, rule-based NLP system (Lockheed Martin, Bethesda, Maryland, USA) built on AeroText (Rocket Software, Newton, Minnesota, USA) and previously successfully used by members of the study team in the Informatics for Integrating Biology and the Bedside (i2b2) obesity challenge.[@R22] [@R30] ClinREAD was chosen because of its availability to the project team and team familiarity with its use. Other valid approaches, including machine learning, were not used because of lack of available resources for the current project. The first stage of the current project involved iterative development and evaluation of NLP-based pain extraction and qualification (severity, anatomy, and date) in the 4409-record PELICAN corpus, for the purposes of discovery over a closed dataset. During this stage, we made iterative modifications to our entire system, data model, normalization rules, and vocabulary (details in online appendix). We tested the generalizability of the NLP methods on 889 unannotated, deidentified discharge summaries provided courtesy of i2b2.[@R31]

The system rated each mention of experienced or explicitly denied pain on the basis of the context in which it was found ([table 1](#AMIAJNL2012001076TB1){ref-type="table"}). We developed 42 pain severity contextual rules, such as (complete list in online appendix table 2): \[pain severity modifier\] \[body location\] \[pain term\]\[pain term\] \[to be\] \[adv\] \[PainSeverityComplement\]\[pain term\] ... \[pain severity complement\] out of \[10\|ten\]

###### 

Example pain severity indicators

                                                       No pain (category 0)   Some pain (category 1)   Controlled pain (category 2)   Severe pain (category 3)
  ---------------------------------------------------- ---------------------- ------------------------ ------------------------------ --------------------------
  Example modifiers (occurring before pain mention)    No                     Some                     Controlled                     Severe
  Without                                              Mild                   Controlling              Significant                    
  No complaint                                         Intermittent           Treatment for            Crushing                       
  Denied any                                           Occasional             Essentially controlled   Excruciating                   
  Absence of                                           Negligible             To control this          Exquisite                      
  Example complements (occurring after pain mention)   Relieved               Dull                     Controlled                     Intractable
  Resolved                                             Not too bad            Managed                  \[8--10\]                      
  0                                                    \[1--7\]               Well managed             \[Eight--ten\]                 
  Zero                                                 \[One--seven\]                                  Unbearable                     
                                                       Persistent                                      Uncontrollable                 

Vocabulary from the Unified Medical Language System (UMLS; version 2010AB)[@R29] was imported via the Metathesaurus from 35 level 0 source vocabularies (see online appendix table 3). We selected 16 semantic types based on the domain of the data as shown in online appendix table 4. Lookup tables were created from each set of synonymous terms in order to associate each phrase with a preferred term and a UMLS concept unique identifier (CUI). A filtering process similar to that of Roberts *et al*[@R32] was used to remove irrelevant terms. After filtering, a total of 675 000 terms and phrases were contained in the study vocabulary.

We combined the vocabulary terms with context patterns in order to recognize internal dates, negatives, conditionals, and pain severity. These context patterns were developed manually. ClinREAD, like MedLEE,[@R33] is rule-based. Each clinical concept ('sign or symptom', 'finding', 'injury or poisoning', 'disease or syndrome', or 'neoplastic process') is associated with a date and a body location; see online appendix for further detail. The system resolved incomplete dates (eg, 'in July') based on the date of the encounter, and resolved relative dates (eg, 'four days prior to admission') based on the previous date mention. Each resolved date is represented as a range (startdate, enddate). This date resolution component was based on the development team\'s previous work[@R34; @R35; @R36; @R37] and is described in the online appendix. When dates were missing, the date of the clinical encounter was used as the default. Date associations were used to normalize the clinical concept to the number of days before death, for each individual study subject. This calculation is enabled through the conversion of the midpoint of absolute date ranges to the modified Julian format.[@R38] Each mention of pain was associated with a severity level from the four-tiered pain scale. A subset of 637 strings from semantic type 'sign or symptom' were identified as indicating pain, listed in online appendix table 5. The NLP algorithm used for the study is summarized in [figure 1](#AMIAJNL2012001076F1){ref-type="fig"} and as follows. Generic processing Text tokenization and sentence detection.Find mentions of dates and numbers; identify the date of the encounter to be used in date resolution.Resolve dates in document order, and calculate Julian format of the midpoint of each date range.Find clinical data (concept extraction) Find mentions of body locations using UMLS vocabulary; look up preferred term.Find mentions of clinical concepts using UMLS vocabulary; look up preferred term.Disambiguate overlapping UMLS vocabulary based on confidence scores associated with each contextual rule. Semantic type disambiguation of overloaded terms was rudimentary; we used context in some cases but relied heavily on default assumptions for terms commonly used in the context of prostate cancer (especially for abbreviations). For the purposes of discovery over a closed corpus, the current disambiguation was effective, as shown by our evaluated performance.Find context information Find context of UMLS vocabulary to identify negations, conditionals, and hypotheticals, and to associate pain severity level, body locations and explicit dates. Context rules were manually built. The negation context rules used much of the same vocabulary as the NegEx algorithm.[@R39] Additional rules to distinguish family history, conditionals, and hypotheticals were manually developed from examination of the dataset.Find negated list sentences ('The patient denies nausea, headache, fevers, or chills.') and negate all concept mentions within them. These predictable sentences were common in the dataset.Convert negated instances of pain concepts to severity scale 0.Clean clinical concept data Associate dates and body locations with UMLS clinical concepts. Use the date of the encounter when an explicit date for the event cannot be determined.Assign CUIs based on vocabulary, severity, semantic type, and body location.Update structured data concepts that lack severity or body locations where the CUI implies them ('severe headache', C0239889).Delete non-pain negatives, conditionals, and hypotheticals from the structured dataset in order to create a set of actual, experienced clinical concepts.Calculate 'days before death' for each clinical concept, using the associated Julian formatted date and a lookup table listing the Julian formatted date of death for each subject in the PELICAN cohort.

![Natural language processing algorithm. CUI, concept unique identifier; UMLS, Unified Medical Language System.](amiajnl-2012-001076f01){#AMIAJNL2012001076F1}

Although our system is proprietary, it could be replicated using other tools. One might start with any system that extracts concepts and identifies assertions as defined for the 2010 i2b2/VA challenge on concepts, assertions, and relations in clinical text.[@R38] One could then integrate a temporal reference extraction and normalization tool such as HeidelTime,[@R40] GATE with the Tagger_DateNormalizer plugin,[@R41] or DANTE,[@R42] filter out the pain-related concepts, as listed in appendix table 5, and identify the level of pain using rules defined in appendix table 2 and the lookup table defined in appendix table 11.

Study database {#s3g}
--------------

NLP processing of the records database produced structured data on each pain mention in each clinical record for all 33 study subjects. These data were combined with demographic and other separately curated data about each subject into a single study database suitable for statistical analysis.

Identification of correlates of severe pain {#s3h}
-------------------------------------------

We undertook a univariate logistic regression analysis to identify correlates of severe pain for use in a multivariate model; factors investigated included receipt of various drugs (eg, opioids, chemotherapy, steroids), body mass index (BMI), receipt of palliative radiation, and frequency of utilization of health services---that is, we correlated severe pain, as derived by NLP processing, with clinical and demographic factors from the structured (ie, non-NLP-based, pre-existing) portion of the study database. For this analysis, 'severe pain' was any reading of controlled or severe pain---that is, any reading of 2 or 3 during a month of observation versus any other reading (−1=no data, 0=explicit report of no pain, 1=reported pain not described as controlled or severe); see online appendix for further details. We then constructed a multiple regression model to assess the strength of associations between the occurrence of severe pain and all defined variables for which p was less than 0.1 in the univariate analysis. Inclusion of a dichotomous variable indicating 'last year before death' controlled for time effects.[@R43] All statistical analyses were conducted with SAS V.9.2 using the Proc Logistic procedure.

Visualization of patients' experience of pain {#s3i}
---------------------------------------------

We determined a pain index value for each subject during four intervals before death, with pain index defined as the mean monthly maximum pain value (max_pain) for months in which a pain report was available; the monthly max_pain values used were no pain=0, some pain=1, and controlled pain or severe pain=2 (see [figure 3](#AMIAJNL2012001076F3){ref-type="fig"}). We then obtained longitudinal views of pain status in each subject by plotting color-coded monthly max_pain values from diagnosis until death ([figure 2](#AMIAJNL2012001076F2){ref-type="fig"}). When no pain status report was available for a given month, we used the most recent pain status as the imputed value for a given subject.

![Study subject pain ribbons 'algograph' display. Maximum pain reported by each subject from prostate cancer diagnosis until time of death from prostate cancer. Pain data are reported for each month. Grey, no report; green, no pain; yellow, pain; orange, controlled pain; red, severe pain.](amiajnl-2012-001076f02){#AMIAJNL2012001076F2}

![Pain index by subject in last months of life. Five African-American subjects have asterisks added to their study subject numbers.](amiajnl-2012-001076f03){#AMIAJNL2012001076F3}

To test the possibility of visualizing a summary of pain records from a group of subjects, we displayed the fraction of study subjects in each pain severity up to the time of death (see online appendix figure 2A), as well as the worst pain severity detected for each subject for each month up to death (see online appendix figure 2b).

Results {#s4}
=======

The purpose of the project was discovery over a closed dataset and a study of feasibility. To evaluate and improve the performance of the NLP algorithm on the dataset, we completed multiple rounds of SME evaluation (GSB and RJT). Across all patient encounters, the NLP algorithm identified 6387 pain mentions (mean 1.45 pain mentions per record) and 13 827 drug mentions.

Evaluation of NLP method within PELICAN clinical text records {#s4a}
-------------------------------------------------------------

After development, we evaluated performance on the closed PELICAN corpus using the AeroText Answer Key Editor. The SMEs separately corrected 32 automatically annotated full text clinical encounter records randomly selected from the entire study set to create 'answer keys'. These 32 records contained 207 mentions of pain. The NLP developers had no influence on the correction of the annotations. Inter-annotator agreement on pain mention (exact token match in the text and normalized concept name), pain start and end date (exact match), body location of pain (exact match), and pain severity integer are shown in [table 2](#AMIAJNL2012001076TB2){ref-type="table"}A, B. We assessed inter-annotator agreement by scoring one annotation set against the other. The entire team then met to discuss and adjudicate the two sets of corrections. Pain mentions on which there were disagreements were resolved to form the gold standard answer key; see online appendix table 6 for examples. We then assessed system performance compared against the gold standard answer key, requiring correct answers (region of text, normalized concept name, body location, and pain severity integer) to be exact matches. Recall is the percentage of pain mentions in the record that were correctly identified by the NLP system. Precision is the percentage of pain mentions identified by the NLP system that are correct. F-measure is the harmonic mean of precision and recall, and provides a measure of overall accuracy. F-measure for pain mention detection was 0.95, and for overall average pain severity assignment was 0.81 (see also [table 3)](#AMIAJNL2012001076TB3){ref-type="table"}.

###### 

Inter-annotator agreement on (A) pain mention, pain start and end date, and body location on the PELICAN corpus, (B) pain severity on the PELICAN corpus, (C) pain mention, pain start and end date, and body location on the i2b2 corpus, and (D) pain severity on the i2b2 corpus

  A---PELICAN corpus      B---PELICAN corpus   C---i2b2 corpus                    D---i2b2 corpus                                                                     
  ----------------------- -------------------- ---------------------------------- ----------------- ----------------------- ------ ---------------------------------- ------
  Pain mention            0.97                 No pain                            0.93              Pain mention            0.88   No pain                            0.81
  Start date of pain      0.93                 Some pain                          0.91              Start date of pain      0.79   Some pain                          0.86
  End date of pain        0.91                 Controlled pain                    0.79              End date of pain        0.74   Controlled pain                    1.00
  Body location of pain   0.76                 Severe pain                        0.85              Body location of pain   0.71   Severe pain                        0.67
                                               Severity of pain overall average   0.88                                             Severity of pain overall average   0.85

i2b2, Informatics for Integrating Biology and the Bedside; PELICAN, Project to ELIminate lethal CANcer.

###### 

Accuracy of natural language processing algorithm extraction of pain mentions regarding (A) pain mention, pain start and end date, and body location on the PELICAN corpus, (B) pain severity on the PELICAN corpus, (C) post-development pain mention, pain start and end date, and body location on the i2b2 corpus, (D) post-development pain severity on the i2b2 corpus

  A---PELICAN corpus      B---PELICAN corpus                                                                                                                                                                                  
  ----------------------- --------------------- --------- -------- -------- ------------ --------------- --------------- ---------------------------------- -------- --------- -------- -------- ------------ --------------- ---------------
  Pain mention            153                   0         7        9        0.96         0.94            0.95            Explicitly no pain                 19       3         2        0        0.79         0.86            0.83
  Start date of pain      145                   8         7        9        0.91         0.90            0.90            Some pain                          75       18        1        8        0.80         0.74            0.77
  End date of pain        145                   8         7        9        0.91         0.90            0.90            Controlled pain                    17       1         2        0        0.85         0.94            0.90
  Body location of pain   51                    1         23       3        0.68         0.93            0.80            Severe pain                        20       0         2        1        0.91         0.95            0.93
                                                                                                                         Severity of pain overall average   131      22        7        9        0.82         0.81            0.81
                                                                                                                                                                                                                              
  **C---i2b2 corpus**     **D---i2b2 corpus**                                                                                                                                                                                 
                          **TP**                **Inc**   **FN**   **FP**   **Recall**   **Precision**   **F-Measure**                                      **TP**   **Inc**   **FN**   **FP**   **Recall**   **Precision**   **F-Measure**
                                                                                                                                                                                                                              
  Pain mention            105                   0         6        17       0.95         0.86            0.90            Explicitly no pain                 18       1         0        3        0.95         0.82            0.88
  Start date of pain      74                    31        6        17       0.67         0.61            0.64            Some pain                          67       10        2        14       0.85         0.74            0.79
  End date of pain        73                    32        6        17       0.66         0.60            0.63            Controlled pain                    5        0         3        0        0.63         1.00            0.81
  Body location of pain   64                    0         42       10       0.60         0.86            0.73            Severe pain                        4        0         1        0        0.80         1.00            0.90
                                                                                                                         Severity of pain overall average   94       11        6        17       0.85         0.77            0.81

FN, false negative; FP, false positive; i2b2, Informatics for Integrating Biology and the Bedside; Inc, incorrect; PELICAN, Project to ELIminate lethal CANcer; TP, true positive.

Evaluation of NLP methods within i2b2 discharge summaries {#s4b}
---------------------------------------------------------

We further evaluated the generalizability of our NLP methods using a blind test set from 889 unannotated, deidentified discharge summaries from i2b2.[@R31] Detailed methods are provided in the online appendix. A test set of 30 discharge summaries (containing 111 pain mentions) was chosen and kept unknown to the NLP developers at all times during the evaluation process. The remaining i2b2 records were designated the 'development set.' Ground truth was created using the same process as the PELICAN evaluation, with the added control that the annotation process was supervised by a developer not involved in the project. Inter-annotator agreement on the i2b2 corpus is shown in [table 2](#AMIAJNL2012001076TB2){ref-type="table"}C, D. The SMEs adjudicated each disagreement to obtain an approved gold standard. Several differences were noted by the SMEs between the i2b2 and the PELICAN clinical record corpora, including an increased frequency of ambiguously dated pain mentions in the i2b2 corpus, as shown by the low inter-annotator agreement for start and end dates in [table 2](#AMIAJNL2012001076TB2){ref-type="table"}C. Further discussion can be found in the online appendix, as can the adjudicated annotations for our 30-report i2b2 test set.

The NLP system was run, as built, on the blind i2b2 test set and scored against the approved gold standard using the AeroText scoring tool. The initial extraction F-measure for pain mentions in the new test set was 0.87; see appendix for complete scores. A 10-hour development process was then conducted to adjust for stylistic differences in the new corpus. The system was scored again, and the system F-measures on pain mentions and pain severity increased to 0.90 and 0.81, respectively.

Date association accuracy was significantly lower than for the PELICAN corpus, falling for start date from 0.90 for PELICAN to only 0.64 for i2b2. We believe that this was the result of a larger number of ambiguous date references in the i2b2 corpus and differences in the annotation guides used by the SMEs to annotate the two corpora; see online appendix for further discussion.

Post-development measures of the NLP extraction over the i2b2 corpus are given in [table 3](#AMIAJNL2012001076TB3){ref-type="table"}; the final NLP extraction of pain in the i2b2 test set is given in the online appendix. Developers remained blind to the test set throughout the development process. The blind evaluation on an independent dataset showed that, with 10 h of development time to adjust for corpus stylistic differences, the NLP system developed for this project is generalizable beyond the PELICAN corpus.

Pain phenotype exploration {#s4c}
--------------------------

Overall, pain increased markedly during the last 2 years of life ([figure 2](#AMIAJNL2012001076F2){ref-type="fig"}). Metastatic prostate cancer was the listed cause of death in all study cases, and none of the subjects was found to have significant additional contributing causes of death. In the final year of life, subject pain index varied widely, from 0.3 to 1.6, with a roughly equal distribution of subjects across this spectrum. The five African-American study subjects clustered at the high end of the pain index spectrum (range 1.3--1.6) ([table 4](#AMIAJNL2012001076TB4){ref-type="table"}).

The system detected no severe or controlled pain in two subjects (8 and 30). The number of clinical encounter records available per year between diagnosis and death for these two subjects was 32 and 19, indicating that the lack of severe pain reports in these two subjects was not due to a lack of clinical encounters. We found no evidence that these subjects died earlier in the course of their disease from non-cancer causes. Since bone pain is the major source of pain in men with metastatic prostate cancer, we reviewed bone scan findings in these two subjects, and both demonstrated widespread bone changes consistent with metastatic prostate cancer, similar to scan results from all other study patients.

Correlates of severe pain {#s4d}
-------------------------

In the initial univariate analysis, all considered variables except for receipt of definitive radiation and maximum recorded BMI correlated significantly with severe pain. African-American ethnicity was borderline associated with severe pain (OR 1.5, p=0.09). Receipt of opiates (OR 25.6, p\<0.001), palliative radiation (OR 13.8, p\<0.0001), and being in the last year of life (OR 9.9, p\<0.001) were strongly associated with severe pain. See online appendix for detailed univariate analysis results.

In the multivariate analysis, only five of the 12 remaining factors were significantly associated with severe pain (p\<0.1): receipt of palliative radiation, opioids, or chemotherapy; being in the last year of life; and the number of outpatient visits ([table 4](#AMIAJNL2012001076TB4){ref-type="table"}). Receipt of non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids or sex-steroid-manipulating drugs were not significantly associated. These findings are consistent with current clinical practice, where palliative radiation[@R44] [@R45] and opioids[@R46] are treatments typically reserved for severe pain, and NSAIDs, corticosteroids, and sex-steroid drugs are used more generally across the pain spectrum.[@R46] Similarly, the last year of life is clinically known to be when severe pain is most common[@R46] and when clinical encounters are most frequent. The multivariate model found no significant association with increasing serum PSA concentration, age at diagnosis, or decline in BMI to \<90% maximum after controlling for the effects of time. There was a non-significant trend associating African-American ethnicity with more severe pain.

###### 

Multivariate regression analysis of natural language processing-detected pain and clinical variables detects clinically expected associations between pain status and administration of palliative radiation and opioid drugs, as well as months before death, and number of inpatient and outpatient visits

  Variable                        OR point estimate   95% CI          p Value
  ------------------------------- ------------------- --------------- ----------
  Received palliative radiation   3.61                1.90 to 6.84    \<0.0001
  Log PSA concentration           1.09                0.86 to 1.38    0.492
  Age at diagnosis                1.00                1.00 to 1.00    0.655
  African-American                1.56                0.80 to 3.05    0.190
  Subject BMI \<90% of maximum    1.02                0.62 to 1.67    0.935
  Chemotherapy administered       1.75                1.01 to 3.04    0.046
  NSAID administered              1.34                0.78 to 2.29    0.284
  Opioid drug administered        6.91                4.07 to 11.74   \<0.0001
  Steroid drug administered       1.21                0.70 to 2.06    0.497
  In last year of life            2.52                1.46 to 4.36    0.001
  Number outpatient visits        1.29                1.12 to 1.48    0.001
  Number inpatient visits         1.30                0.75 to 2.26    0.350

BMI, body mass index; NSAID, non-steroidal anti-inflammatory drug; PSA, prostate-specific antigen.

The model and findings were robust, explaining 83% of the variability in the data. When we excluded six patients who were seen only in a community setting and who had fewer recorded clinical encounters, the patterns of association remained unchanged. Moreover, when we removed from the model all variables that were not significant in the univariate analysis, the strengths of the associations (adjusted ORs) of the remaining variables and p values changed only marginally.

Discussion {#s5}
==========

In multivariate regression analysis, pain status detected by NLP correlated statistically with parameters clinically known to be associated with increased pain. Conversely, pain status detected by NLP was not associated with parameters not expected to be clinically associated with pain status, such as administration of definitive radiation with curative intent. These results suggest that meaningful NLP-based pain status monitoring is feasible. While this project used a rule-based NLP system, machine-learning-based NLP tools should be tested in future work.

Text in longitudinal data is valuable for the study of symptoms such as pain, where the clinical unstructured description may be more complete than it is in structured data.[@R28] NLP techniques convert such unstructured data into structured data, which is typically more amenable to rigorous analysis and display.

Relief of pain is essential in the management of many acute and chronic diseases, and convenient automated monitoring of patient pain status could provide a valuable new tool for improving quality of life and care. Real-time, easy-to-interpret views of the pain status history of an individual patient or a group of patients, as shown in [figure 2](#AMIAJNL2012001076F2){ref-type="fig"} and online appendix figure 2, could allow busy clinicians to identify patients most in need of increased pain management intensity, and allow researchers to perform visual and quantitative comparison of groups of subjects participating in clinical trials of novel therapies or novel clinical interventions.

NLP-based determination of pain status may help to identify clinically significant molecular differences between prostate cancers. For example, a study of the molecular differences in the cancers of the two men who apparently experienced no severe pain could provide important clues to the biological determinants of severe pain in metastatic prostate cancer. Similarly, the trend toward increased pain experienced by the five African-Americans compared with the other men in the study is consistent with an oncology clinical trial which found that African-American men were more likely than white men to have extensive disease and bone pain.[@R47]

Limitations and future directions {#s5a}
---------------------------------

Our study has several limitations. First, the dataset was relatively small, covering just 33 patients. Second, it was difficult to distinguish pain mentions that were not related to the subjects' metastatic prostate cancer. Although SME review of the records revealed only rare examples of pain not related to prostate cancer in the current study, future studies should implement formal methods to identify and link pain to a relevant disease source. Third, it was difficult to distinguish pain control status from the patient\'s current experience of pain. This study defaulted to 'controlled' pain as one of the pain categories because there were multiple records where the patient was noted to be taking opioids for pain, but no current pain level was provided. Fourth, we may have slightly biased our annotation of the PELICAN corpus by using system outputs to initialize annotations. This technique has been shown to improve consistency, reduce annotation time,[@R48] and improve inter-annotator agreement.[@R49] [@R50] We minimized possible bias by having the annotators work independently and by submitting the results to team scrutiny and collaborative discussion. In essence, the answer key was generated by compiling the answers of four (overlapping) SMEs: two humans, the system itself, and the team as a whole. The similar evaluation results obtained on the separate i2b2 corpus, which used isolated test and development sets, suggest that any bias was minimal. Finally, the use of proprietary ClinREAD and AeroText NLP software may limit reproducibility. However, this limitation is at least partially mitigated by our provision of detailed rules, as well as results from our analysis of the i2b2 corpus. Investigators interested in further analysis of the study dataset using other methods and under appropriate confidentiality protection are invited to contact the senior author.

Conclusions {#s6}
===========

Electronic health records have greatly facilitated detection and understanding of disease phenotypes and their relationship with genetic and non-genetic factors.[@R51; @R52; @R53; @R54; @R55] The study reported here, which we believe to be the first to use NLP to obtain longitudinal pain status information in a cohort of patients, shows that NLP-based monitoring of patient pain status is feasible and generalizable to new datasets, and provides a number of phenotype-oriented observations useful for guiding future research. Future studies should focus on comparison of pain-status tracking by NLP versus other validated pain survey tools, and on practical integration of the two methods in settings where electronic health records are in routine use.
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